Review top news and interview highlights from the week ending February 4, 2022.
Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Cell and gene therapies are currently being evaluated as possible avenues of treatment for multiple inherited retinal diseases. We’re spotlighting promising therapies currently in development.
The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed challenges of currently available strategies for managing hemophilia A and B, including adherence to factor replacement therapy.
The first patient has been dosed in the phase 1/2 trial (NCT05197270) of the gene therapy 4D-150 (4D Molecular Therapeutics) for the potential treatment of wet age-related macular degeneration (wet AMD).
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies. He also touched oncilta-cel's place in the multiple myeloma treatment landscape.
The FDA has approved Immunocore's tebentafusp-tebn (Kimmtrak) for the treatment of HLA-A*02:01–positive unresectable or metastatic uveal melanoma.